共 50 条
- [1] A phase I study of guadecitabine (SGI-110) plus cisplatin in patients with platinum refractory germ cell tumorsJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Albany, CostantineSpinella, Michael J.Adra, NabilHanna, Nasser H.Einhorn, Lawrence
- [2] Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients (pts) with platinum-refractory germ cell tumors (GCT): Preliminary results from an open label phase 1b studyJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Hashemi-Sadraei, NedaEinhorn, Lawrence H.Perkins, SusanSpinella, Michael J.Fang, FangHanna, Nasser H.Nephew, Kenneth P.Albany, Costantine
- [3] Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Crabb, Simon J.Huddart, Robert A.Brown, EmmaDunkley, DeniseDowns, NicholaMcDowell, CathyCatto, James W. F.Griffiths, Gareth OwenDanson, SarahReid, Alison Helen
- [4] A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancerCANCER MEDICINE, 2021, 10 (01): : 156 - 163Albany, CostantineFazal, ZeeshanSingh, RatnakarBikorimana, EmmanuelAdra, NabilHanna, Nasser H.Einhorn, Lawrence H.Perkins, Susan M.Sandusky, George E.Christensen, Brock C.Keer, HaroldFang, FangNephew, Kenneth P.Spinella, Michael J.
- [5] Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumorsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)Papadatos-Pastos, DionysisYuan, WeiPal, AbhijitCrespo, MateusFerreira, AnaGurel, BoraProut, TobyAmeratunga, MalakaChenard-Poirier, MaximeCurcean, AndraBertan, ClaudiaBaker, ChloeMiranda, SusanaMasrour, NahalChen, WentinPereira, RitaFigueiredo, InesMorilla, RicardoJenkins, BenZachariou, AnnaRiisnaes, RuthParmar, MonaTurner, AlisonCarreira, SuzanneYap, ChristinaBrown, RobertTunariu, NinaBanerji, UdaiLopez, Juanitade Bono, JohannMinchom, Anna
- [6] Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyLANCET ONCOLOGY, 2015, 16 (09): : 1099 - 1110Issa, Jean-Pierre J.Roboz, GailRizzieri, DavidJabbour, EliasStock, WendyO'Connell, CaseyYee, KarenTibes, RaoulGriffiths, Elizabeth A.Walsh, KatherineDaver, NavalChung, WoonbokNaim, SueTaverna, PietroOganesian, AramHao, YongLowder, James N.Azab, MohammadKantarjian, Hagop
- [7] Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Adra, NabilAlthouse, Sandra K.Ammakkanavar, Natraj ReddyRadovich, MilanAlbany, CostantineVaughn, David J.Einhorn, Lawrence H.Hanna, Nasser H.
- [8] Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)BLOOD, 2018, 132Garcia-Manero, GuillermoSasaki, KojiMontalban-Bravo, GuillermoBodden, Kristy R.Bose, PrithvirajAlvarado, YesidDaver, Naval G.Borthakur, GautamRavandi, FarhadTakahashi, KoichiCortes, Jorge E.Jabbour, Elias J.Naqvi, KiranDiNardo, Courtney D.Benton, Christopher B.Pemmaraju, NaveenKadia, Tapan M.Ohanian, Maro N.Pierce, Sherry A.Kantarjian, Hagop M.
- [9] Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumorsJOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5403 - 5407Bedano, Pablo M.Brames, Mary J.Williams, Stephen D.Juliar, Beth E.Einhorn, Lawrence H.
- [10] Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trialINVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1080 - 1086Mego, M.Svetlovska, D.De Angelis, VKalavska, K.Lesko, P.Makovnik, M.Obertova, J.Orszaghova, Z.Palacka, P.Reckova, M.Rejlekova, K.Sycova-Mila, Z.Mardiak, J.Chovanec, M.